Lymphoma Patients Suing Monsanto Get Favorable Appeals Ruling

According to a press release issued yesterday, a panel of three judges from Missouri's Eastern District Court of Appeals has rejected a claim by Missouri-based agricultural biotech company Monsanto that they are not responsible for people who have developed non-Hodgkin's lymphoma from exposure to PCBs, or polychlorinated biphenyls.

This effectively reverses a lower court decision and means the appeals court felt there was enough evidence for the case to proceed to trial.

A pending lawsuit

The case centers on three plaintiffs who say they had no occupational exposure to PCBs and yet nonetheless have high levels in their blood. They are the first of several hundred people with non-Hodgkin's lymphoma who have high PCB levels and who are moving ahead with similar lawsuits.

Because of the enormous implications of this decision, part of the press release will be reprinted here verbatim:

The case represents the first time that injured victims have sought to hold a company accountable for producing a chemical that has contaminated the entire planet, including every person in the United States. The plaintiffs are three lymphoma patients who each have elevated levels of PCBs in their blood. The original Monsanto Co. [now known as "Pharmacia Corp."] produced more than 99 percent of all of the PCBs ever used in the United States. Because PCBs are far more persistent in the environment than most other chemicals, PCBs are now a ubiquitous environmental contaminant. Today, PCBs can be found in measurable levels in virtually any sample of soil or air and also in the food chain. PCBs contaminate fish, dairy products, beef, pork, poultry and eggs.

PCBs have a connection to non-Hodgkin's lymphoma

Additionally, the International Agency for Research on Cancer has confirmed the cancer-causing potential of PCBs – which have been banned in the United States since 1979. PCBs have been linked to non-Hodgkin's lymphoma.

The Missouri Supreme Court is next, and this case could go to trial in 2014.

Source: MarketWatch

Photo: "Public inspection" of the Monsanto facility at Enkhuizen, Netherlands, by Luther Blissett

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap